Loading patent…
AssigneeZymoGenetics, Inc.
InventorsWenfeng Xu, Wayne Kindsvogel, Yasmin Chandrasekher, Stacey Dillon, Joyce Lehner, Anthony Siadak, Pallavur Sivakumar, Margaret Moore
Estimating the term…
The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
A method of producing an antibody to a polypeptide comprising:
An antibody or antibody fragment that binds to a polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:3;
A method of treating a mammal afflicted with an inflammatory disease in which IL-22 or IL-20 plays a role, comprising:
A method of treating a mammal afflicted with an inflammatory disease in which IL-22 and IL-20 plays a role, comprising:
An antibody comprising a monoclonal antibody that specifically binds to an antigenic epitope of human IL-22RA (SEQ ID NO:3) selected from the group consisting of:
A method of treating a mammal afflicted with an inflammatory disease in which IL-22RA plays a role, comprising:
Dependencies are inferred from the claim text.